홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
CALC
#3866
CalciMedica, Inc. Common Stock
0.5
2
-7.14%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-7.14%
월간 변동
-38.10%
6달 변화
-82.07%
년간 변동율
-78.78%
이전 종가
0.5
6
Open
0.5
2
Bid
Ask
Low
0.5
2
High
0.5
2
양
4
마켓
주식
헬스케어
CALC
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.5 M
1.53 M
1.57 M
10.74 M
13.48 M
—
Valuation ratios
Enterprise value
—
—
—
27.39 M
39.79 M
—
Price to earnings ratio
—
—
—
-0.4
-2.9
-6.89
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
0.53
1.88
5.89
Price to book ratio
—
—
—
1.69
2.76
4.96
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.27
-0.52
-0.9
-2.82
-0.69
-1.25
Return on equity %
-0.29
-0.55
-0.99
-4.21
-0.95
-30.85
Return on invested capital %
-1 588.65
-2 042.52
-3 529.04
-9 642.06
-9 496.42
-12.38 K
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
14.18
16.53
10.72
2.88
5.34
20.48
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
0
—
—
Long term debt to total equity ratio
—
—
—
0
—
—
Per share metrics
Operating cash flow per share
—
—
-14.91
-5.74
-1.88
-1.57
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
25.49
2.5
1.66
5.6
Net current asset value per share
—
—
25.84
2.59
1.75
5.84
Tangible book value per share
—
—
23.43
1.82
1.28
2.45
Working capital per share
—
—
23.43
1.69
1.42
4.71
Book value per share
—
—
23.43
1.82
1.28
2.45
뉴스
칼시메디카, 임상 중단 후 H.C. Wainwright, ’중립’으로 등급 하향
CalciMedica stock downgraded to Neutral by H.C. Wainwright after trial halt
칼시메디카, 2상 KOURAGE 임상시험 중단 권고에 따라 중단
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.02%
칼시메디카, 신장 손상 임상 중단 후 주가 폭락
칼시메디카, 안전 문제로 AKI 임상시험 중단
CalciMedica discontinues AKI trial following safety concerns
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis - CalciMedica (NASDAQ:CALC)
Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial
CalciMedica partners with Telperian to use AI for clinical trial analysis
칼시메디카 CBO, 7,675달러 상당 자사주 매입